leadf
logo-loader
viewAerie Pharmaceuticals

Aerie Pharmaceuticals in spotlight as FDA judges Rhopressa eye drop

The FDA will decide on Aerie’s Rhopressa eye drop this morning

eye
The stock's trading was halted

Aerie Pharmaceuticals Inc (NASDAQ:AERI) is in the spotlight on Friday as the US Food and Drugs Administration is set to judge an application for its new eye drug.

Trading in the stock is on hold this morning as the FDA’s dermatologic and opthalmic drugs advisory committee will meet to review Aerie’s Rhopressa eye drop.

Rhopressa is intended to be a once daily application designed to reduce pressure on eyes resulting from glaucoma.

Quick facts: Aerie Pharmaceuticals

Price: 15.5 USD

NASDAQ:AERI
Market: NASDAQ
Market Cap: $727.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

MetalNRG assembles 'secret weapon' team for Sunswept Enterprise as...

MetalNRG PLC's (LON:MNRG) Rolf Gerritsen and Pierpaolo Rocco talk to Proactive London about the Sunswept Enterprise Limited transaction which is now complete.  This follows confirmation from the Oil & Gas Authority that it does not oppose the change of control of Sunswept Enterprise...

43 minutes ago

2 min read